{"filing":{"accession_number":"0001640334-26-001302","cik":"0001348362","ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-04","primary_document":"lxrp_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033426001302/lxrp_8k.htm"},"events":[{"id":26704,"run_id":24280,"accession_number":"0001640334-26-001302","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Lexaria received a delisting notification from Nasdaq on August 4, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Although the company completed a reverse stock split and filed a hearing request to stay delisting, the core disclosure is a notice of delisting risk—the unmistakable signal that the registrant has failed a continued listing standard and faces suspension from trading absent successful appeal or compliance recovery.","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27923,"accession_number":"0001640334-26-001302","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Lexaria received a delisting notification from Nasdaq on August 4, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Although the company completed a reverse stock split and filed a hearing request to stay delisting, the core disclosure is a notice of delisting risk—the unmistakable signal that the registrant has failed a continued listing standard and faces suspension from trading absent successful appeal or compliance recovery.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T00:01:22.434296+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27923,"accession_number":"0001640334-26-001302","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Lexaria received a delisting notification from Nasdaq on August 4, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Although the company completed a reverse stock split and filed a hearing request to stay delisting, the core disclosure is a notice of delisting risk—the unmistakable signal that the registrant has failed a continued listing standard and faces suspension from trading absent successful appeal or compliance recovery.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T00:01:22.434296+00:00","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-08-10"}]}